Case (n = 81) | Control (n = 81) | p-value | ||||
---|---|---|---|---|---|---|
Comorbidities | ||||||
Hypertension | 71(87.6) | 59 (72.8) | 0.018 | |||
Cardiovascular diseases | 17 (20.9) | 12 (14.8) | 0.306 | |||
Diabetes mellitus | 26 (32.0) | 26(32.0) | 1.000 | |||
Others* | 27 (33.3) | 22 (27.2) | 0.421 | |||
Body mass index, Kg/m2 | 24 ± 4.3 | 24 ± 3.9 | 0.945 | |||
Previous treatments | 56 (69.1) | 47 (58.0) | 0.141 | |||
Type of previous treatments | ||||||
Conservative | 36 (64.3) | 30 (37.0) | 0.337 | |||
Peritoneal dialysis | 19 (33.9) | 9 (11.1) | 0.038 | |||
Hemodialysis | 17 (30.4) | 9 (11.1) | 0.087 | |||
Transplant | 15 (26.8) | 8 (9,9) | 0.115 | |||
Duration of hemodialysis treatment, months | 29 ± 39.2 | 36 ± 42.1 | 0.276 | |||
Type of current venous access | ||||||
AVF** | 25 (30.9) | 64 (79.0) | <0.001 | |||
Tunneled hemodialysis CVC*** | 52 (64.2) | 13 (16.0) | ||||
Non-tunneled hemodialysis CVC | 4 (4.9) | 1 (1.2) | ||||
PTFE Graft**** | 0 (-) | 3 (3.7) | ||||
Location of current venous access | ||||||
Upper arm | 24 (29.6) | 67 (82.7) | ||||
Jugular vein | 50 (61.7) | 13 (16.0) | ||||
Subclavian vein | 7 (8.6) | 0 (-) | ||||
Femoral vein | 0 (-) | 1 (1.2) | ||||
Duration of current venous access | ||||||
0–30 | 17 (21,0) | 3 (3.7) | <0.001 | |||
30–180 days | 27 (33.3) | 8 (9.9) | ||||
>180 days | 37 (45.7) | 70 (86.4) | ||||
Previous venous access (6 months) | 26 (32.1) | 11 (13.6) | 0.005 | |||
Number of previous accesses | 1.2 ± 0.41 | 1.3 ± 0.46 | 0.744 | |||
Type of previous venous access | ||||||
AVF | 7 (8.6) | 3 (3.7) | 0.192 | |||
Tunneled hemodialysis CVC | 14 (17.3) | 5 (6.2) | 0.028 | |||
Non-tunneled hemodialysis CVC | 5 (6.2) | 6 (7.4) | 0.755 | |||
PTEF Graft | 5 (6.2) | 1 (1.2) | 0.210 | |||
Location of tunneled hemodialysis CVC | ||||||
Jugular vein | 13 (16.0) | 3 (3.7) | ||||
Subclavian vein | 0 (-) | 1 (1.2) | ||||
Location of non-tunneled hemodialysis CVC | ||||||
Jugular vein | 4 (4.9) | 6 (7.4) | ||||
Subclavian vein | 1 (1.2) | 0 | ||||
Duration of previous venous access | ||||||
AVF | ||||||
0–30 | 0 | 1 (1.2) | ||||
30–180 days | 4 (4.9) | 0 (-) | ||||
>180 days | 3 (3.7) | 2 (2.5) | ||||
Tunneled hemodialysis CVC | ||||||
0–30 | 4 (4.9) | 0 (-) | 0.034 | |||
30–180 days | 6 (7.4) | 5 (6.2) | ||||
>180 days | 4 (4.9) | 0 (-) | ||||
Non-tunneled hemodialysis CVC | ||||||
0–30 | 1 (1.2) | 6 (7.4) | ||||
30–180 days | 3 (3.7) | 0 | ||||
>180 days | 1 (1.2) | 0 | ||||
PTFE Graft** | ||||||
0–30 | 0 (-) | 0 (-) | ||||
30–180 days | 1 (1.2) | 0 (-) | ||||
>180 days | 4 (4.9) | 1 (1.2) | ||||
Transfusions | 11 (13.6) | 7 (8.6) | 0.317 | |||
Number of transfusions | 1.9 ± 2.7 | 1 (-) | 0.246 | |||
Hospitalizations due to infection | 21 (25.9) | |||||
Length of hospital stay | 16.9 ± 16.4 | |||||
Previous use of antimicrobials | 28 (34.6) | 14 (17.3) | 0.012 | |||
Previous hospitalizations | 19 (23.5) | 4 (4.9) | <0.001 | |||
Number of previous hospitalizations | 1.5 ± 1.2 | 1(-) | 0.259 |